Close Menu
  • Home
  • Vaccines
  • Politics
  • Health
  • Tech
  • Sports
  • Research
  • Fitness
  • Careers
What's Hot

Health Canada approves Novartis’ KISQALI® for HR+/HER2- early breast cancer patients at high risk of recurrence

Sheriff, county lawyer seeking mental health funds at Minnesota State Capitol

Chronic absences have not disappeared. Research shows that poor children are most hurt.

Facebook X (Twitter) Instagram
subjectional.com
Subscribe
  • Home
  • Vaccines
  • Politics
  • Health
  • Tech
  • Sports
  • Research
  • Fitness
  • Careers
subjectional.com
Home » Explore 3 high-growth Swiss tech stocks
Featured Tech

Explore 3 high-growth Swiss tech stocks

Paul E.By Paul E.October 28, 2024No Comments5 Mins Read
Share Facebook Twitter Pinterest Copy Link Telegram LinkedIn Tumblr Email
Share
Facebook Twitter LinkedIn Pinterest Email


The Swiss market has recently experienced modest gains, with the SMI index closing slightly higher amid cautious investor sentiment and limited market incentives. In this environment, identifying high-growth tech stocks requires careful consideration of companies that not only demonstrate solid innovation and adaptability, but also the resilience to weather fluctuating economic conditions.

name

increase in revenue

revenue growth

growth assessment

LEM Holding

8.81%

20.48%

★★★★★☆

Sunterra Pharmaceuticals Holding

26.80%

35.40%

★★★★★★

ALSO Holdings

12.58%

26.76%

★★★★☆

comet holding

20.43%

48.65%

★★★★★★

software one holding

8.55%

52.33%

★★★★★☆

Chicor Technologies

6.78%

27.45%

★★★★☆

Adex Therapeutics

26.51%

33.31%

★★★★★☆

Basilea Pharmaceutica

9.23%

26.82%

★★★★★☆

Sensirion Holdings

13.86%

102.68%

★★★★☆

MCH Group

4.41%

100.62%

★★★★☆

Click here to see the complete list of 12 stocks in SIX Swiss Exchange’s High Growth Technology Stocks and AI Stock Screener.

We’re going to check out some of our picks from the screener tool.

Simply Wall Street Growth Rating: ★★★★★☆

Overview: Basilea Pharmaceutica AG is a commercial stage biopharmaceutical company specializing in the development of oncology and anti-infective products with a market capitalization of CHF 543.63 million.

Business Operations: The Company derives its revenues primarily from the discovery, development and commercialization of innovative medicines, amounting to CHF 149.02 million. Its operations are focused on addressing medical needs in oncology and anti-infective diseases.

Basilea Pharmaceutica stands out for its strategic advances in the pharmaceutical sector, even in a challenging financial environment characterized by an annual revenue growth forecast of 9.2%. The company recently strengthened its market position through the approval of Pediatric Cresemba by the EC and increased market exclusivity. This not only strengthens the product portfolio but also promises a sustainable revenue stream with an additional milestone of CHF 10 million from Pfizer. Additionally, Basilea’s commitment to innovation is evidenced by its research and development investments aimed at expanding therapeutic applications. With revenues expected to soar by 26.8% annually, these strategic initiatives could significantly shape Basilea’s trajectory in the high-growth technology sector in Switzerland’s competitive environment.

story continues

SWX:BSLN revenue and revenue growth (as of October 2024)

Simply Wall Street Growth Rating: ★★★★★★

Overview: Comet Holding AG has a market capitalization of CHF 2.32 billion and operates worldwide through its subsidiaries, providing X-ray and radio frequency (RF) power technology solutions to Europe, North America, Asia and other international markets. I am.

Business activities: Comet Holding AG mainly operates from three segments: X-ray systems (CHF 115.34 million), industrial X-ray modules (CHF 95.9 million) and plasma control technology (CHF 180.62 million). We are making a profit. The company serves diverse international markets with a focus on providing advanced technology solutions in the fields of X-ray and RF power.

Comet Holding AG has overcome a difficult financial environment and demonstrated resilience, with sales increasing to CHF 189.32 million and net profit doubling to CHF 4.06 million in the first half of 2024. Ta. This performance represents an expected annual revenue growth rate of 20.4%, which is higher than the Swiss market average of 4.1%. Additionally, Comet’s revenue is expected to grow by approximately 48.6% annually over the next three years, reflecting a solid strategic position despite the highly volatile recent share price. These figures not only highlight Comet’s commitment to innovation, but also hint at Comet’s potential trajectory in the Swiss technology industry amidst increasing competition and evolving industry demands.

SWX:COTN revenue and revenue growth (as of October 2024)

Simply Wall Street Growth Rating: ★★★★★☆

Overview: LEM Holding SA together with its subsidiaries provides solutions for measuring electrical parameters across various regions including China, Japan, Korea, India, Southeast Asia, Europe, Middle East, Africa, NAFTA and Latin America. The company’s market capitalization is CHF 1.38 billion.

Operations: LEM Holding specializes in providing electrical measurement solutions to various regions. The company primarily generates revenue through its services in this field, with a particular focus on international markets such as Asia, Europe, and the Americas.

In the competitive Swiss technology environment, LEM Holding shows promising growth prospects, with annual sales expected to increase by 8.8% and profits by 20.5%. These numbers not only highlight the company’s solid strategic position, but also its commitment to innovation, highlighted by significant R&D investments that are consistent with these growth projections. Despite facing challenges such as higher levels of debt and lower profit margins compared to previous years, LEM Holding’s financial strategy (including recent share buybacks) aims to boost investor confidence. This reflects the company’s proactive management actions. The company is currently well-positioned for future advances in electronics, with a projected three-year return on equity of 29.3%, which could outperform broader market expectations.

SWX:LEHN Breakdown of revenue and expenses as of October 2024

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts using only unbiased methodologies, and articles are not intended to be financial advice. This is not a recommendation to buy or sell any stock, and does not take into account your objectives or financial situation. We aim to provide long-term, focused analysis based on fundamental data. Note that our analysis may not factor in the latest announcements or qualitative material from price-sensitive companies. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include SWX:BSLN SWX:COTN and SWX:LEHN.

Do you have feedback on this article? Interested in its content? Please contact us directly. Alternatively, email us at editorial-team@simplywallst.com.



Source link

Follow on Google News Follow on Flipboard
Share. Facebook Twitter Pinterest LinkedIn Tumblr Email Copy Link
Previous ArticleLive sports viewers are increasingly embracing digital
Next Article Tappy Technologies unveils world’s first fitness ring with network card tokenization for contactless payments at Hong Kong Fintech Week 2024
Paul E.
  • Website

Related Posts

Tamarack Global Closes $72 Million Opportunity II Fund to Advance Deep Technology and Industrial Innovation

October 31, 2024

Inside Super Micro’s wake-up call: After riding the AI wave, the $20 billion tech giant is crashing back to earth amid a financial crisis and family drama

October 31, 2024

Northern Hockey and Tech Hockey open CCHA season with rivalry series

October 31, 2024
Leave A Reply Cancel Reply

Latest Posts

Health Canada approves Novartis’ KISQALI® for HR+/HER2- early breast cancer patients at high risk of recurrence

Sheriff, county lawyer seeking mental health funds at Minnesota State Capitol

Chronic absences have not disappeared. Research shows that poor children are most hurt.

Transport Secretary reveals overhaul of aging pneumatic transport systems

Latest Posts

Subscribe to News

Subscribe to our newsletter and never miss our latest news

Subscribe my Newsletter for New Posts & tips Let's stay updated!

Welcome to Subjectional!

At Subjectional, we believe that informed opinions are the foundation of a vibrant society. Our mission is to provide insightful, engaging, and balanced information across a diverse range of topics that matter to you. Whether you’re interested in the latest developments in health, navigating the complexities of politics, staying updated on sports, exploring technological advancements, or advancing your career, we’ve got you covered.

Facebook X (Twitter) Instagram Pinterest YouTube

Subscribe to Updates

Subscribe to our newsletter and never miss our latest news

Subscribe my Newsletter for New Posts & tips Let's stay updated!

Facebook X (Twitter) Instagram Pinterest
  • Home
  • About Us
  • Advertise with Us
  • Contact us
  • DMCA
  • Privacy Policy
  • Terms & Conditions
© 2025 subjectional. Designed by subjectional.

Type above and press Enter to search. Press Esc to cancel.